Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Other Operating Expenses data on file, last reported at $47.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 70.76% year-over-year to $47.4 million; the trailing twelve-month figure through Mar 2026 stood at $47.4 million (up 31.78% YoY), and the FY2024 full-year result was $8.2 million, up 48229.41% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $47.4 million, up from -$6000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $47.4 million in Q1 2026 and bottomed at -$36000.0 in Q3 2024.
• The 4-year median for Other Operating Expenses is $39000.0 (2023), against an average of $7.6 million.
• The widest annual swing landed in 2024, when Other Operating Expenses tumbled 192.31%; it then jumped 86643.75% in 2025.
• A 4-year view of Other Operating Expenses shows it stood at $62000.0 in 2023, then soared by 13093.55% to $8.2 million in 2024, then sank by 100.07% to -$6000.0 in 2025, then surged by 790100.0% to $47.4 million in 2026.
• The last three Other Operating Expenses figures came in at $47.4 million (Q1 2026), -$6000.0 (Q4 2025), and -$25000.0 (Q3 2025), per Business Quant data.

Peer Comparison